The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms
We herein present an overview of the upcoming 5th edition of the World Health Organization
Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid …
Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid …
Mantle-cell lymphoma
JO Armitage, DL Longo - New England Journal of Medicine, 2022 - Mass Medical Soc
Mantle-Cell Lymphoma Accounting for 5 to 7% of all lymphomas, mantle-cell lymphoma has
historically been associated with a poor outcome, but survival is improving. The …
historically been associated with a poor outcome, but survival is improving. The …
The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee
Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium
PURPOSE Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric
antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell …
antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell …
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
CW Eskelund, C Dahl, JW Hansen… - Blood, The Journal …, 2017 - ashpublications.org
Despite recent advances in lymphoma treatment, mantle cell lymphoma (MCL) remains
incurable, and we are still unable to identify patients who will not benefit from the current …
incurable, and we are still unable to identify patients who will not benefit from the current …
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
Y Song, K Zhou, D Zou, J Zhou, J Hu… - Blood, The Journal …, 2022 - ashpublications.org
Bruton tyrosine kinase (BTK) inhibitor is an established treatment for relapsed/refractory
(R/R) mantle cell lymphoma (MCL). Zanubrutinib, a highly selective BTK inhibitor, is …
(R/R) mantle cell lymphoma (MCL). Zanubrutinib, a highly selective BTK inhibitor, is …
Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments
P Jain, ML Wang - American journal of hematology, 2022 - Wiley Online Library
The field of mantle cell lymphoma (MCL) has witnessed remarkable progress due to
relentless advances in molecular pathogenesis, prognostication, and newer treatments …
relentless advances in molecular pathogenesis, prognostication, and newer treatments …
Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management
Unprecedented advances in our understanding of the pathobiology, prognostication, and
therapeutic options in mantle cell lymphoma (MCL) have taken place in the last few years …
therapeutic options in mantle cell lymphoma (MCL) have taken place in the last few years …
A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas
Several editions of the World Health Organization (WHO) classifications of lympho-
hemopoietic neoplasms in 2001, 2008 and 2017 served as the international standard for …
hemopoietic neoplasms in 2001, 2008 and 2017 served as the international standard for …
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M Dreyling, E Campo, O Hermine… - Annals of …, 2017 - annalsofoncology.org
Mantle cell lymphoma (MCL) is a relatively uncommon subtype of lymphoid malignancy and
represents 5%–7% of malignant lymphoma in Western Europe. The annual incidence of this …
represents 5%–7% of malignant lymphoma in Western Europe. The annual incidence of this …